Peregrine Capital Management LLC Lowers Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Peregrine Capital Management LLC lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 25.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 344,532 shares of the specialty pharmaceutical company's stock after selling 114,658 shares during the quarter. Peregrine Capital Management LLC owned about 1.06% of Collegium Pharmaceutical worth $10,605,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in COLL. Envestnet Asset Management Inc. raised its stake in Collegium Pharmaceutical by 23.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 16,028 shares of the specialty pharmaceutical company's stock valued at $326,000 after purchasing an additional 3,058 shares during the period. American Century Companies Inc. raised its stake in Collegium Pharmaceutical by 26.2% during the 1st quarter. American Century Companies Inc. now owns 128,780 shares of the specialty pharmaceutical company's stock valued at $2,622,000 after purchasing an additional 26,760 shares during the period. Citigroup Inc. raised its stake in Collegium Pharmaceutical by 11.0% during the 1st quarter. Citigroup Inc. now owns 43,381 shares of the specialty pharmaceutical company's stock valued at $883,000 after purchasing an additional 4,292 shares during the period. PNC Financial Services Group Inc. raised its stake in Collegium Pharmaceutical by 233.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,224 shares of the specialty pharmaceutical company's stock valued at $44,000 after purchasing an additional 1,558 shares during the period. Finally, Bank of Montreal Can increased its stake in Collegium Pharmaceutical by 9.2% in the 1st quarter. Bank of Montreal Can now owns 11,850 shares of the specialty pharmaceutical company's stock worth $239,000 after acquiring an additional 1,001 shares during the last quarter.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 23,560 shares of the business's stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $32.28, for a total transaction of $760,516.80. Following the completion of the transaction, the executive vice president now owns 111,322 shares in the company, valued at approximately $3,593,474.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.69% of the stock is owned by company insiders.

Collegium Pharmaceutical Trading Down 1.6 %

Shares of Collegium Pharmaceutical stock traded down $0.63 on Tuesday, reaching $38.79. The company had a trading volume of 204,177 shares, compared to its average volume of 442,214. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of 32.87 and a beta of 1.03. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10. The firm's 50-day moving average price is $36.48 and its two-hundred day moving average price is $30.20. Collegium Pharmaceutical, Inc. has a 1 year low of $20.83 and a 1 year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts' consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The firm had revenue of $149.75 million during the quarter, compared to analysts' expectations of $147.66 million. As a group, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, February 2nd. Jefferies Financial Group reaffirmed a "hold" rating and issued a $37.00 price objective (up previously from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Truist Financial lifted their price objective on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a "buy" rating in a research note on Monday, February 26th. Piper Sandler reaffirmed an "overweight" rating and issued a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a research note on Friday, February 23rd. Finally, StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Friday, March 29th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $39.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.